Mercer Global Advisors’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$477K Buy
6,366
+1,162
+22% +$74.6K ﹤0.01% 2337
2026
Q1
$293K Sell
5,204
-1,144
-18% -$74.5K ﹤0.01% 2460
2025
Q4
$509K Buy
+6,348
New +$427K ﹤0.01% 1849
2024
Q4
Sell
-3,919
Closed -$310K 2182
2024
Q3
$310K Sell
3,919
-2,022
-34% -$163K ﹤0.01% 1595
2024
Q2
$491K Buy
5,941
+1,718
+41% +$151K ﹤0.01% 1313
2024
Q1
$360K Sell
4,223
-412
-9% -$32.3K ﹤0.01% 1460
2023
Q4
$396K Sell
4,635
-53
-1% -$4.58K ﹤0.01% 1459
2023
Q3
$420K Buy
4,688
+148
+3% +$13.2K ﹤0.01% 1336
2023
Q2
$387K Buy
4,540
+358
+9% +$30.3K ﹤0.01% 1358
2023
Q1
$346K Buy
4,182
+319
+8% +$25.8K ﹤0.01% 1425
2022
Q4
$304K Sell
3,863
-1,106
-22% -$88.9K ﹤0.01% 1493
2022
Q3
$368K Sell
4,969
-98
-2% -$7.04K ﹤0.01% 1296
2022
Q2
$330K Buy
+5,067
New +$300K ﹤0.01% 1378
2021
Q3
Sell
-4,781
Closed -$319K 1780
2021
Q2
$319K Sell
4,781
-1,136
-19% -$80.4K ﹤0.01% 1358
2021
Q1
$657K Buy
+5,917
New +$732K 0.01% 954

Other funds holding HAE

Mercer Global Advisors's HAE Position: Q2 2026 in Review

Mercer Global Advisors increased its Haemonetics (HAE) stake by 22% in Q2 2026, buying an estimated $74.6K and bringing the position to 6,366 shares worth $477K. The position accounts for ﹤0.01% of the portfolio, ranked #2337.

Mercer Global Advisors first reported a position in HAE in Q1 2021 and has held it in 15 quarters since. The position peaked at $657K in Q1 2021. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Mercer Global Advisors held 6,366 shares of Haemonetics worth $477K as of Q2 2026.
  • Mercer Global Advisors bought 1,162 Haemonetics shares in Q2 2026, an estimated $74.6K.
  • Haemonetics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #2337 holding.
  • Mercer Global Advisors first reported a position in Haemonetics in Q1 2021 and has held it in 15 quarters since.
  • Mercer Global Advisors's Haemonetics position peaked at $657K in Q1 2021.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.